Gene Enlightenment Secures Over RMB 100 Million in New Financing Led by Renhe Capital
Gene Key
Developer of Immune Cell Product Technologies and Provider of Clinical Application Services
Investment Circle (ID: pedaily2012) January 23rd news, recently, Beijing Gene Key Life Technology Co., Ltd. (hereinafter referred to as: Gene Key)CompletedExceeding 100 Million YuanNew Round of Financing Led by Renhe CapitalThe financing funds will be mainly used for the clinical trials of the company's iNKT cell therapy products and the research and development of new product pipelines, etc.
Gene Key Life Technology Co., Ltd. was established in 2015 as the world's first leading company to develop a series of iNKT cell pipeline products; it has a team dedicated to fundamental biomedical and immunology research, an iNKT cell research platform, and a clinical research platform.
Feng Jikai, founder of Beijing Gene Key Life Technology Co., Ltd., stated, we thank Renhe Capital for its recognition of Gene Key Life Technology. This financing represents another significant milestone in the company’s development. Gene Key Life Technology will accelerate product research and development, further solidify its leading position in the iNKT cell therapy field, and strive to achieve commercialization as soon as possible.
Mr. Jin Weichun, founding partner of Renhe Capital, stated,Cell therapy is an innovative drug research and development direction with significant clinical and market value, following small-molecule and large-molecule drugs. The iNKT cell therapy product developed by Beijing Gene Key Life Technology Co., Ltd has demonstrated excellent safety and its clinical efficacy has been preliminarily validated. We look forward to the company's product reaching the market soon to benefit patients.